These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25185192)

  • 21. [Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?].
    Vis AN; van Moorselaar RJA
    Ned Tijdschr Geneeskd; 2019 Nov; 163():. PubMed ID: 32073798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 23. Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator.
    Mistry HB; Fabre MA; Young J; Clack G; Dickinson PA
    CPT Pharmacometrics Syst Pharmacol; 2016 May; 5(5):258-63. PubMed ID: 27299938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
    Matsubara N; Mukai H; Hosono A; Onomura M; Sasaki M; Yajima Y; Hashizume K; Yasuda M; Uemura M; Zurth C
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1063-1072. PubMed ID: 28801852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
    Hakariya T; Sakai H
    Nihon Rinsho; 2016 Jan; 74(1):137-42. PubMed ID: 26793894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sequential therapy for castration-resistant prostate cancer].
    Nozawa M; Uemura H
    Nihon Rinsho; 2016 May; 74 Suppl 3():644-8. PubMed ID: 27344809
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for targeting the androgen receptor axis in prostate cancer.
    Carver BS
    Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alternative antiandrogen therapy for castration-resistant prostate cancer].
    Suzuki H; Utsumi T; Endo T; Kamijima S; Kamiya N
    Nihon Rinsho; 2016 May; 74 Suppl 3():589-94. PubMed ID: 27344799
    [No Abstract]   [Full Text] [Related]  

  • 31. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer.
    Dorff TB; Tsao-Wei DD; Groshen S; Boswell W; Goldkorn A; Xiong S; Quinn DI; Pinski JK
    Clin Genitourin Cancer; 2013 Dec; 11(4):416-22. PubMed ID: 24099865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
    Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
    Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
    Luo J; Beer TM; Graff JN
    Oncology (Williston Park); 2016 Apr; 30(4):336-44. PubMed ID: 27085332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A new androgen receptor antagonist : Darolutamide for patients with non-metastatic castration-resistant prostate cancer].
    Kesch C; Hadaschik BA
    Urologe A; 2019 Oct; 58(10):1217-1218. PubMed ID: 31471641
    [No Abstract]   [Full Text] [Related]  

  • 37. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Branch JR; Bush TL; Pande V; Connolly PJ; Zhang Z; Hickson I; Ondrus J; Jaensch S; Bischoff JR; Habineza G; Van Hecke G; Meerpoel L; Packman K; Parrett CJ; Chong YT; Gottardis MM; Bignan G
    Mol Cancer Ther; 2021 May; 20(5):763-774. PubMed ID: 33649102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer.
    Ban F; Dalal K; LeBlanc E; Morin H; Rennie PS; Cherkasov A
    Mol Inform; 2018 Sep; 37(9-10):e1800043. PubMed ID: 29733509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Darolutamide (Nubeqa) for prostate cancer.
    Med Lett Drugs Ther; 2019 Dec; 61(1587):201-202. PubMed ID: 31999669
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.